Biosynex (France) Performance
| ALBIO Stock | EUR 2.62 0.02 0.77% |
The firm shows a Beta (market volatility) of 0.24, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Biosynex's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biosynex is expected to be smaller as well. At this point, Biosynex has a negative expected return of -0.92%. Please make sure to confirm Biosynex's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Biosynex performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biosynex has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 36.8 M | |
| Total Cashflows From Investing Activities | -29 M |
Biosynex |
Biosynex Relative Risk vs. Return Landscape
If you would invest 506.00 in Biosynex on September 2, 2024 and sell it today you would lose (244.00) from holding Biosynex or give up 48.22% of portfolio value over 90 days. Biosynex is generating negative expected returns and assumes 3.7531% volatility on return distribution over the 90 days horizon. Simply put, 33% of stocks are less volatile than Biosynex, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biosynex Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biosynex's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biosynex, and traders can use it to determine the average amount a Biosynex's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2448
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALBIO |
Estimated Market Risk
| 3.75 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.92 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biosynex is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biosynex by adding Biosynex to a well-diversified portfolio.
Biosynex Fundamentals Growth
Biosynex Stock prices reflect investors' perceptions of the future prospects and financial health of Biosynex, and Biosynex fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biosynex Stock performance.
| Return On Equity | 0.89 | |||
| Return On Asset | 0.45 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 91.77 M | |||
| Shares Outstanding | 10.25 M | |||
| Price To Earning | 48.98 X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 0.46 X | |||
| Revenue | 382.53 M | |||
| EBITDA | 139.33 M | |||
| Cash And Equivalents | 1.98 M | |||
| Cash Per Share | 0.22 X | |||
| Total Debt | 29.16 M | |||
| Debt To Equity | 17.70 % | |||
| Book Value Per Share | 17.24 X | |||
| Cash Flow From Operations | 109.83 M | |||
| Earnings Per Share | 6.37 X | |||
| Total Asset | 268.94 M | |||
| Retained Earnings | (5 M) | |||
| Current Asset | 6 M | |||
| Current Liabilities | 4 M | |||
About Biosynex Performance
Assessing Biosynex's fundamental ratios provides investors with valuable insights into Biosynex's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Biosynex is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France. BIOSYNEX is traded on Paris Stock Exchange in France.Things to note about Biosynex performance evaluation
Checking the ongoing alerts about Biosynex for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biosynex help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biosynex generated a negative expected return over the last 90 days | |
| Biosynex has high historical volatility and very poor performance | |
| About 58.0% of the company shares are held by company insiders |
- Analyzing Biosynex's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biosynex's stock is overvalued or undervalued compared to its peers.
- Examining Biosynex's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biosynex's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biosynex's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biosynex's stock. These opinions can provide insight into Biosynex's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biosynex Stock Analysis
When running Biosynex's price analysis, check to measure Biosynex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosynex is operating at the current time. Most of Biosynex's value examination focuses on studying past and present price action to predict the probability of Biosynex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosynex's price. Additionally, you may evaluate how the addition of Biosynex to your portfolios can decrease your overall portfolio volatility.